Compared with Pareja's DCIS cohort,[22] we observed that high‐frequency mutations in our DCIS cohort were almost consistent with that in Pareja's cohort, including TP53 (DCIS cohort in this study versus Pareja's DCIS cohort, 50% versus 44%; p > 0.05). This evidence concerns the gene TP53 and ductal breast carcinoma in situ.